NAMS

NewAmsterdam Pharma Company N.V. Ordinary Shares

$31.79 -5.61%

Recent alerts on NAMS

All signals →

Insider trade Sale by Kooij Louise Frederika (Chief Accounting Officer)

News NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

News NewAmsterdam Pharma reports Q1 results

SEC filing NAMS Reports $707.3M Cash, $19B Net Income, +94% YoY, Announces 2H26 EMA Approval, 4Q26 Menarini Launch, 4Q26 PREVAIL Interim, 1Q27 Result, RUBENS Data Year-End 2026

SEC filing NAMS Announces $8B+ Peak Sales Potential for Obicetrapib, 45% Lp(a) Lowering, $729M Cash Position

Insider trade Sale by Mayur Ian Somaiya

Get push alerts for NAMS

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS